Use of Oral Droxidopa to Improve Arterial Pressure and Reduce Vasoactive Drug Requirements During Persistent Vasoplegic Syndrome After Cardiac Transplantation
Section snippets
Case Presentation
A 53-year-old woman (100 kg, 170 cm) with end-stage nonischemic cardiomyopathy and bridge-to-transplant left ventricular assist device support (HeartWare, Framingham, MA) was transported to the operating room for orthotopic cardiac transplantation (the left ventricular ejection fraction of the donor heart was estimated to be 60%). The patient was treated chronically with oral amiodarone before surgery, but not an angiotensin-converting enzyme inhibitor. The patient’s initial intraoperative
Discussion
Droxidopa is a synthetic catecholamine-like amino acid that was first synthesized almost 100 years ago. The chemical structure of droxidopa is similar to another synthetic amino acid, the prototypical Parkinson’s disease medication L-3,4-dihydroxyphenylalanine (L-DOPA). Droxidopa has been available for clinical use in Japan since 1989.11 The US Food and Drug Administration recently approved droxidopa for the treatment of neurogenic orthostatic hypotension, and initial clinical trials
References (26)
- et al.
Vasoplegia during cardiac surgery: Current concepts and management
Semin Thorac Cardiovasc Surg
(2010) - et al.
Human cytokine responses to cardiac transplantation and coronary artery bypass grafting
J Thorac Cardiovasc Surg
(1996) Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass
J Thorac Cardiovasc Surg
(1991)- et al.
Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent
J Thorac Cardiovasc Surg
(1998) - et al.
Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function
Ann Thorac Surg
(2001) - et al.
Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?
J Thorac Cardiovasc Surg
(2003) - et al.
Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa
Biochem Pharmacol
(1987) - et al.
Hypotension, acidosis, and vasodilatation syndrome post-heart transplant: Prognostic variables and outcomes
J Heart Lung Transplant
(2001) - et al.
Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions
J Crit Care
(2013) - et al.
Vasoplegic syndrome after open heart surgery
J Cardiovasc Surg (Torino)
(1998)
Methylene blue: Potential use of an antique molecule in vasoplegic syndrome during cardiac surgery
Expert Rev Cardiovasc Ther
Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome
Circulation
Risk factors and outcomes for ‘vasoplegia syndrome’ following cardiac transplantation
Eur J Cardiothorac Surg
Cited by (5)
Vasoplegic syndrome during heart transplantation: A systematic review and meta-analysis
2024, Journal of Heart and Lung TransplantationDroxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients
2024, Journal of Cardiothoracic and Vascular AnesthesiaThe International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients
2023, Journal of Heart and Lung TransplantationVasoplegic syndrome in patients undergoing heart transplantation
2023, Frontiers in SurgeryVasoplegia in patients following ventricular assist device explant and heart transplantation
2022, Perfusion (United Kingdom)